Craig Howard Olson1. 1. Division of Colon and Rectal Surgery, University of Texas Southwestern, 1801 Inwood Blvd WA3.316, Dallas, TX, 75390, USA. Craig.olson@utsouthwestern.edu.
Abstract
PURPOSE OF REVIEW: To summarize the current available treatments for stage I rectal cancer and the evidence that supports them. RECENT FINDINGS: Radical surgery, or total mesorectal excision (TME) without neoadjuvant therapy, reports excellent oncologic outcomes, with 5-year disease-free survival of approximately 95%. Alternative therapies include local excision, which has acceptable long-term outcomes in some low-risk T1 tumors; but overall local excision, with or without additional chemotherapy or radiation, generally reports 5-year disease-free survival less than TME alone. New research is showing complete clinical response rates of 67% with chemoradiation combined with additional consolidation chemotherapy in T2 lesions, making watch and wait a potential strategy for stage I tumors. Owing to its superior oncologic outcomes, radical surgery remains the mainstay of treatment for stage I tumors. Both local excision and watch and wait have advantages that may make them useful in individual patients and should be considered under the right circumstances.
PURPOSE OF REVIEW: To summarize the current available treatments for stage I rectal cancer and the evidence that supports them. RECENT FINDINGS: Radical surgery, or total mesorectal excision (TME) without neoadjuvant therapy, reports excellent oncologic outcomes, with 5-year disease-free survival of approximately 95%. Alternative therapies include local excision, which has acceptable long-term outcomes in some low-risk T1 tumors; but overall local excision, with or without additional chemotherapy or radiation, generally reports 5-year disease-free survival less than TME alone. New research is showing complete clinical response rates of 67% with chemoradiation combined with additional consolidation chemotherapy in T2 lesions, making watch and wait a potential strategy for stage I tumors. Owing to its superior oncologic outcomes, radical surgery remains the mainstay of treatment for stage I tumors. Both local excision and watch and wait have advantages that may make them useful in individual patients and should be considered under the right circumstances.
Entities:
Keywords:
Local excision; Rectal cancer; Stage I; Total mesorectal excision; Watch and wait
Authors: A C Kraima; N P West; D Treanor; D R Magee; H J Rutten; P Quirke; M C DeRuiter; C J H van de Velde Journal: Eur J Surg Oncol Date: 2015-04-02 Impact factor: 4.424
Authors: R D Blok; R Stam; E Westerduin; W A A Borstlap; R Hompes; W A Bemelman; P J Tanis Journal: Eur J Surg Oncol Date: 2018-04-12 Impact factor: 4.424
Authors: Przemysław Wawok; Wojciech Polkowski; Piotr Richter; Marek Szczepkowski; Janusz Olędzki; Ryszard Wierzbicki; Tomasz Gach; Andrzej Rutkowski; Adam Dziki; Leszek Kołodziejski; Rafał Sopyło; Lucyna Pietrzak; Jacek Kryński; Katarzyna Wiśniowska; Mateusz Spałek; Konrad Pawlewicz; Marcin Polkowski; Teresa Kowalska; Krzysztof Paprota; Małgorzata Jankiewicz; Andrzej Radkowski; Justyna Chalubińska-Fendler; Wojciech Michalski; Krzysztof Bujko Journal: Radiother Oncol Date: 2018-04-18 Impact factor: 6.280
Authors: Garrett M Nash; Martin R Weiser; José G Guillem; Larissa K Temple; Jinru Shia; Mithat Gonen; W Douglas Wong; Philip B Paty Journal: Dis Colon Rectum Date: 2009-04 Impact factor: 4.585
Authors: Andrew R L Stevenson; Michael J Solomon; John W Lumley; Peter Hewett; Andrew D Clouston; Val J Gebski; Lucy Davies; Kate Wilson; Wendy Hague; John Simes Journal: JAMA Date: 2015-10-06 Impact factor: 56.272
Authors: Alisha Lussiez; Samantha J Rivard; Kamren Hollingsworth; Sherif R Z Abdel-Misih; Philip S Bauer; Katherine A Hrebinko; Glen C Balch; Lillias H Maguire Journal: Dis Colon Rectum Date: 2021-12-27 Impact factor: 4.412